tbuckley/cabot-search huggingface dataset:
Intersectional monosynaptic tracing for dissecting subtype-specific organization of GABAergic interneuron inputs
Authors: Michael J. Yetman, Eric Washburn, Jung Ho Hyun, Fumitaka Osakada, Yasufumi Hayano, Hongkui Zeng, Edward M. Callaway, Hyung-Bae Kwon, Hiroki Taniguchi
Journal: Nature Neuroscience (2019)
Multicentric, Retrospective Study of Extracorporeal Photopheresis, Off-Line System, in Corticosteroid Refractory Acute and Chronic Graft-Versus-Host Disease
Authors: Gillen Oarbeascoa, Maria Luisa Lozano, Luisa Maria Guerra, Cristina Amunarriz, Nuria Revilla, Iniesta Pastora, Cynthia Acosta Fleitas, Jose Luis Arroyo, Eva Martinez Revuelta, Andrea Galego, Dolores Hernandez-Maraver, Mi Kwon, Jose Luis Díez-Martín, Aurora Viejo, Jose Maria Garcia-Gala, Concepcion Andon Saavedra, Cristina Pascual, (GEA) Grupo Español de Aferesis
Journal: Blood (2018)
SAT0484 Performance of the 2017 eular/acr classification criteria for inflammatory myositis and their major subgroups in the remicam (REGISTRY OF INFLAMMATORY MYOPATHIES IN THE MADRID COMMUNITY)
Authors: E. Rabadán, B.E. Joven, F. Lozano, L. Nuño, F.J. López-Longo, J. Martínez-Barrios, C. Larena, M. Blazquez, C. Barbadillo, I. Llorente, A. Pérez, T. Cobo, R. Almodovar, L. Lojo, R. Calvo, M.J. García de Yébenes, P.E. Carreira
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> A collaborative EULAR/ACR Project has developed new criteria for inflammatory myopathies(IM) and their subgoups<sup>1</sup> <h3>Objectives</h3> To analyse agreement between the 2017 IM classification criteria and the Bohan and Peter(BP) criteria in REMICAM cohort<sup>2</sup> <h3>Methods</h3> All patients were included. New criteria were applied to obtain classification as: possible(Pos), probable(Pro) and definitive(Def) IM, and subclassification in 6 subgroups: polymyositis(PM), dermatomyositis(DM), juvenile DM(JDM), amiopathic DM(ADM), inclusion body myositis(IBM) and juvenile myositis(JM). The 7 subgroups in REMICAM were harmonised to fit the 6 subgroups of the 2017 criteria. Agreement between 2017 and BP criteria was analysed in classification/subclassification, calculating the weighted kappa value (k). Subanalysis including only patients with available data on the muscle strength items required for the 2017 criteria, and in those having also muscle biopsy data, were conducted. <h3>Results</h3> From 479 REMICAM patients, 477 (99.6%), fulfilled BP criteria (5.9%Pos, 26.8%Pro, 67.4%Def) and 431 (89.9%) 2017 criteria (2.5%Pos, 21.8%Pro, 65.7Def). Global agreement between both criteria was 89.5%. Agreement between subtypes (Pos, Pro, Def) was low (k=0.15). When 399 patients with muscle strength data, and 243 with muscle biopsy data were analysed, results were similar (k=0.17). Disagreement was mainly seen in Pos/Pro subtypes with BP criteria, since 60% classified as Def when the 2017 criteria were applied. Agreement in the different subgroups of IM (PM, DM, JDM, ADM, IBM, JM) between both criteria was very high (k=0.94). <h3>Conclusions</h3> The new 2017 EULAR/ACR criteria for IM classification show good agreement with BP criteria in the REMICAM cohort. New criteria classify 60% of Pos/Pro patients by BP criteria, as Def, and show very high agreement between IM subgroups. Validation studies are needed, but our results in this large cohort suggest the 2017 criteria might be useful for clinical trials and research in IM. <h3>References</h3> [1] Lundberg IE. Ann Rheum Dis2017;76:1955–64. [2] Nuño L. Rheumatol Clin2017;13:331–7. <h3>Disclosure of Interest</h3> None declared
AB0589 Relevance of b and t cell subsets to lupus flare in korean patients with systemic lupus erythematosus
Authors: J.H. Koh, N. Lee, W.-U. Kim
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with heterogeneous clinical manifestations and is characterised with autoreactive T cells and autoantibody overproduction by activated B cells. <h3>Objectives</h3> The aims of this study were to characterised T-cell and B-cell subpopulation phenotype in Korean patients with SLE, and to elucidate the association between lymphocyte subpopulation and lupus activity. <h3>Methods</h3> We used multicolor flow cytometry to analyse subsets of peripheral blood B-cells (defined by CD19, IgD, CD27, and CD38) and T-cells (CD3, CD4, CD8, CD45RA, CCR7) in 26 patients with SLE and 22 age- and sex-matched healthy subjects. Baseline and 6 month follow-up SLE disease activity index (SLEDAI) was recorded, and SLEDAI score ≥6 was considered as lupus flare-up. Lymphocyte phenotype was also compared between stable disease and lupus flare-up. <h3>Results</h3> The number of B cells and CD8 +T cells were not different between SLE patients and healthy subjects; however, non-switched memory (NSwM) B cells was decreased in SLE patients. Double negative (DN) T cells, CD4 +T cells and its subset [naïve, central memory (CM), effector memory (EM) and terminally differentiated effector memory (TEMRA) cells] were decreased in SLE patients compared to healthy controls. Patients with lupus flare-up showed significantly decreased CD4 +and DN T cells, whereas CD4 +EM T cells were increased in patients with lupus flare up, compared to stable SLE. SLEDAI was correlated with DN T cells (<i>ρ</i>=−0.728, p<i>&lt;</i>0.001), CD4 +CM T cells (<i>ρ</i>=−0.544, p=0.004), CD4 +EM T cells (<i>ρ</i>=−0.697, p<i>&lt;</i>0.001) and CD8 +EM T cells (<i>ρ</i>=−0.408, p=0.039). Six (23%) patients experienced lupus flare and a patient presented still high disease activity at 6 month follow-up visit. Interestingly, these patients showed the low number of DN T cells, CD4 +EM and TEMRA cells at baseline when they were stable. <h3>Conclusions</h3> Biassed differentiation of T-cells was associated with lupus flare and aggravation of SLE 6 months later. Understanding T cell subset enables accurate stratification of lupus flare-up and personalised approach. <h3>References</h3> [1] Nakayamada S, Iwata S, Tanaka Y. Relevance of lymphocyte subsets to B cell-targeted therapy in systemic lupus erythematosus. Int J Rheum Dis2015;18:208–218. [2] Anolik JH, Barnard J, Owen T, Zheng B, Kemshetti S, Looney RJ, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum2007;56:3044–3056. [3] Tsokos, G. C., M. S. Lo, P. C. Reis, and K. E. Sullivan. 2016. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol12: 716–730. <h3>Acknowledgements</h3> We wish to thank Jihoon Kwon, the M.S. student for his excellent support. <h3>Disclosure of Interest</h3> None declared
In HF with secondary mitral regurgitation, transcatheter mitral valve repair reduced HF hospitalizations at 2 years
Authors: Anthony Donato, Eric Elgin
Journal: Annals of Internal Medicine (2019)

Source Citation Stone GW, Lindenfeld J, Abraham WT, et al; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018;Sep 23. [Epub ahead of print]. 30280640
AB0750 Rheumatic diseases with lung involvment and psychological status
Authors: D. Abdulganieva, N. Shamsutdinova, G. Nurullina, E. Kirillova, E. Makaricheva, A. Krasnov, A. Surikov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> assess the impact of psychological status indicators on lung function in patients with rheumatic diseases with lung lesions <h3>Methods</h3> A study of 30 patients with diagnoses of systemic scleroderma (SSD) – 14 patients, systemic vasculitis (CB) – 10, rheumatoid arthritis (RA) – 6 patients. The average age of the patients was 56.55±10.59 (from 22 to 77 years). All patients had high activity of the underlying disease and received pathogenetic therapy in the form of pulse therapy for HA – 19 patients, high doses of HA (1 mg/kg) per os – 11 patients; were hospitalised in connexion with the first detected lung lesions or signs of progression of the existing lung injury (increased dyspnea, reduced exercise tolerance). Patients are consulted by a cardiologist to exclude the cardiac genesis of symptoms. All patients underwent a standard clinical examination, in addition they performed: high-resolution RCT of lung (64-slice CT system Philips Diamond Select Brilliance), a 6 min walk test. Evaluation of lung function was carried out using spirometry, bodipletizmography, diffusion "single breath". The following scales were used to assess the psychological status: State-Trait Anxiety Inventory (STAIpersonal and situational anxiety assessment, symptomatic questionnaire SCL-90-R (English Simptom Check List-90-Revised), anxiety and depression, the Toronto Alexitimic Scale (TAS) <h3>Results:</h3> All patients according to RKT data had manifestations of IZL in the form of nonspecific interstitial pneumonia. Among the patients examined, the group with DV 1st. was 11 patients, DN 2 tbsp. – 14 patients, DN 3 tbsp. – 5 patients.A high level of situational anxiety was present in 11 patients (36.7%), personal – in 13 patients (43.3%). At the same time, the DLCO relationship to the alveolar volume was identified with the level of personal anxiety (r=−0.526, p&lt;0.05) and situational (r=−0.423, p&lt;0.05). In addition, the DV index has an average correlation with the level of anxiety (r=0.513, p&lt;0.05). The symptomatic questionnaire revealed a significant degree of somatization in patients with IBD – in 14 patients (46.7%), which is the somatic equivalent of depression and anxiety.TAS data indicate the presence of apparent alexithymia in 10 patients (33.3%), the "risk group" for alexithymia is 26.7%. In addition, saturation after a 6 min walk was correlated with alexithymia (r=−0.526, p&lt;0.05). <h3>Conclusions:</h3> The psychological status of patients with rheumatic diseases with lung involvement in the form of nonspecific interstitial pneumonia is characterised by depression, anxiety, alexithymia. <h3>Disclosure of Interest:</h3> None declared
Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura
Authors: Marie Scully, Spero R. Cataland, Flora Peyvandi, Paul Coppo, Paul Knöbl, Johanna A. Kremer Hovinga, Ara Metjian, Javier de la Rubia, Katerina Pavenski, Filip Callewaert, Debjit Biswas, Hilde De Winter, Robert K. Zeldin
Journal: New England Journal of Medicine (2019)

In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which result in thrombocytopenia, hemolytic anemia, and tissue ischemia. Caplacizumab, an anti–von Willebrand factor humanized, bivalent variable-domain-only immunoglobulin fragment, inhibits interaction between von Willebrand factor multimers and platelets.
FRI0214 Clinical evaluation correlates poorly with ultrasound and magnetic resonance imaging of joints and entheses in early peripheral spondyloarthritis
Authors: T. Renson, P. Carron, S. Krabbe, L. Jans, A.-S. De Craemer, M. de Hooge, P. Jacques, M. Ostergaard, D. Elewaut, F. Van den Bosch
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Enthesitis is a hallmark of spondyloarthritis (SpA), which occurs in 30% to 50% of psoriatic arthritis patients (pts).<sup><sup>1</sup></sup> Evaluation of tenderness at the site of an enthesis with a standard palpation approach remains the gold standard for detection of enthesitis. However, inter- and intra-observer variability is rather high. All existing clinical enthesitis scoring systems lack validity. Imaging could avoid these drawbacks. <h3>Objectives</h3> To compare the performance of ultrasound (US) and magnetic resonance imaging (MRI) with clinical examination (CE) of joints and entheses in peripheral (p)SpA. <h3>Methods</h3> Clinical REmission in peripheral SPondyloArthritis (CRESPA) is a placebo-controlled trial of golimumab treatment in 60 early (symptom duration &lt;12 weeks) pSpA pts. CE included tender and swollen joint count, dactylitis and enthesitis (evaluation of palpation tenderness) count. All pts underwent Power Doppler (PD)US of entheses and knee, talocrural (TC) and subtalar (ST) joints. Synovitis was scored according to the OMERACT-EULAR-US composite PDUS scale, giving a score of 0–3 for each joint. Entheseal sites were evaluated for hypoechogenicity and intraenthesis Doppler signal and were scored on a scale of 0–3. Modified whole-body MRI was performed at baseline. Bone marrow oedema (BME), synovitis and soft tissue inflammation (STI) were scored (scale 0–3) by 3 readers at several anatomical sites of pelvis and lower limbs. For each site a mean of the scores of the 3 readers was calculated. <h3>Results</h3> Synovitis detected by US and MRI was most prevalent at knee joints (table 1). A discrepancy was noted between TC synovitis detected by CE, US and MRI. Enthesitis was most prevalent at Achilles tendon and plantar fascia. Regarding enthesitis, agreement between CE and US ranged from no (kappa −0.082) to moderate agreement (kappa 0.562). The highest agreement was observed at the entheseal sites of Achilles tendon (left 0.511, right 0.350) and plantar fascia (left 0.321, right 0.507). MRI did not correlate better with CE than US (kappa from −0.077 to 0.446). The correlation between MRI and US was overall poor and only in the Achilles tendon moderate (range −0.106 to 0.656). <h3>Conclusions</h3> There was a weak agreement between CE and imaging in detecting enthesitis. In general, US detects less enthesitis compared to CE, while MRI detects more. <h3>Reference</h3> [1] Gladmann DD, Chadran V. Observational cohort studies: Lessons learnt from the university of Toronto Psoriatic Arthritis Program. Rheumatology2011;50(1):25–31. <h3>Disclosure of Interest</h3> None declared
Biomarker cruises in sepsis: who is the CAPTAIN? Discussion on “Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study”
Authors: George Briassoulis, Panagiotis Briassoulis, Marianna Miliaraki, Stavroula Ilia, Marianna Parlato, François Philippart, Alexandra Rouquette, Virginie Moucadel, Jean-Marc Cavaillon, Benoît Misset
Journal: Intensive Care Medicine (2019)
Abstract 16225: Durability of Left Atrial Linear Ablation and Clinical Outcome After Catheter Ablation for Persistent Atrial Fibrillation
Authors: Tae-Hoon Kim, Junbeom Park, Jae-Sun Uhm, Jong-Youn Kim, Boyoung Joung, Moon-Hyoung Lee, Hui-Nam Pak
Journal: Circulation (2016)

Introduction: It is not clear whether bidirectional block (BDB) of linear ablations reduces AF recurrence after RFCA. Hypothesis: We hypothesized that BDB of linear ablation has prognostic significance after RFCA for persistent AF (PeAF). Methods: Among 1793 consecutive patients in Yonsei AF ablation Cohort, we included 398 patients with PeAF (75.6% male, 59.8±10.3years old) who underwent catheter ablation with consistent ablation protocol of Dallas lesion set: CPVI, cavotricuspid isthmus ablation (CTI), roof line (RL), postero-inferior line (PIL), and anterior line (AL). Results: BDB rates of de novo ablation lines were 100% in CPVI, 100% in CTI, 84.7% in RL, 44.7% in PIL, and 63.6% in AL. During the 29.0±18.4 months of follow-up, 31.7% (126/398) showed clinical recurrence. Left atrial posterior wall (LAPW) isolation (BDBs of RL and PIL) was independently associated with lower clinical recurrence (HR 0.68, 95% CI 0.47~0.98, p=0.041, Log-rank p=0.017), whereas those with BDB of RL or AL were not (Log-rank...
AB0128 Cxcl1, but not auto-antibodies or cd4+ccr6+ memory th cells within blood, is a marker to differentiate mice into collagen induced arthritispositive or negative prior to clinically manifest disease
Authors: M. Molendijk, A.M. Mus, P.S. Asmawidjaja, E. Lubberts
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> There is currently a knowledge gap on early pathogenesis prior to Rheumatoid Arthritis (RA) diagnosis. Additionally, current medication available for RA treatment has not been developed for prevention. Collagen induced arthritis (CIA) could aid in extending knowledge on early RA pathogenesis and testing the preventive effects of medicines. <h3>Objectives</h3> In this study we sought a marker that can differentiate mice prior to clinically manifest disease into their future CIA status with the aim to facilitate research into early disease processes and preventive treatment strategies. <h3>Methods</h3> Blood was obtained at time points prior (days 12 and 19) and after clinically manifest disease (days 27 and 35) during CIA. Antibodies against bovine and mouse collagen type II (mCII) were measured from plasma by ELISA. CD4<sup>+</sup>CCR6<sup>+</sup> memory Th cells as well as other T cell types were determined in blood. Cytokines and chemokines were detected in plasma by Luminex. Mice were divided into CIA negative and CIA positive groups based on CIA score reached on day 35. <h3>Results</h3> Antibodies against mCII of the IgG2a isotype differed prior to clinically manifest disease but are not suitable as a differentiation marker. CD4<sup>+</sup>CCR6<sup>+</sup> memory Th cells in blood differed only at day 35. The same holds for IL-6, TNFα and CXCL2. In contrast, CXCL1 differed prior to clinically manifest disease with an AUC significantly better (p=0.003) than random. <h3>Conclusions</h3> Here we identified CXCL1 as a marker that can differentiate mice prior to clinically manifest disease into CIA positive and CIA negative mice. This might help facilitate research into early disease processes and preventive pre-clinical treatment strategies. <h3>Disclosure of Interest</h3> None declared
Abstract 17280: The Effect of Long-Term Administration of PGE1 on the Morphological Change of Ductus Arteriosus
Authors: Ryuma Iwaki, Hironori Matsuhisa, Yoshihiro Oshima, Masato Hoshino, Naoto Yagi, Toru Akaike, Susumu Minamisawa, Gen Shinohara, Kiyozo Morita, Hiroyuki Morishita, Yukihiro Kaneko, Masashi Takahashi, Takuro Tsukube, Yutaka Okita
Journal: Circulation (2017)

Introduction: Plostagrandin E1 (PGE1) is essential to maintain the ductus arteriosus (DA) in ductal-dependent congenital heart diseases. Recently, relatively long-term administration of PGE1 became...
Macrophage and Fibroblast Interactions in Biomaterial‐Mediated Fibrosis
Authors: Claire E. Witherel, Daniel Abebayehu, Thomas H. Barker, Kara L. Spiller
Journal: Advanced Healthcare Materials (2019)

Biomaterial-mediated inflammation and fibrosis remain a prominent challenge in designing materials to support tissue repair and regeneration. Despite the many biomaterial technologies that have been designed to evade or suppress inflammation (i.e., delivery of anti-inflammatory drugs, hydrophobic coatings, etc.), many materials are still subject to a foreign body response, resulting in encapsulation of dense, scar-like extracellular matrix. The primary cells involved in biomaterial-mediated fibrosis are macrophages, which modulate inflammation, and fibroblasts, which primarily lay down new extracellular matrix. While macrophages and fibroblasts are implicated in driving biomaterial-mediated fibrosis, the signaling pathways and spatiotemporal crosstalk between these cell types remain loosely defined. In this review, the role of M1 and M2 macrophages (and soluble cues) involved in the fibrous encapsulation of biomaterials in vivo is investigated, with additional focus on fibroblast and macrophage crosstalk in vitro along with in vitro models to study the foreign body response. Lastly, several strategies that have been used to specifically modulate macrophage and fibroblast behavior in vitro and in vivo to control biomaterial-mediated fibrosis are highlighted.
First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study
Authors: Arnon P. Kater, Peter Hillmen, Barbara Eichhorst, Anton W Langerak, Thomas J. Kipps, Carolyn Owen, Michelle Boyer, Kathryn Humphrey, Elizabeth A Punnoose, Jue Wang, Brenda Chyla, Maria E. Verdugo, Jenny Wu, Yanwen Jiang, Mehrdad Mobasher, John F. Seymour
Journal: Blood (2018)
Drug-Eluting Stents
Authors: T. Cooper Woods, Andrew R. Marks
Journal: Annual Review of Medicine (2004)

Advances in catheter and stent design have made stent implantation the standard coronary angioplasty procedure. Unfortunately, in-stent restenosis continues to plague this procedure, with the optimum binary restenosis rates reaching ~10% to 20%. In the past few years, it has become clear that in-stent restenosis is largely due to the migration and proliferation of vascular smooth muscle cells to form a neointima. To address this issue, stents coated with drug-delivery vehicles have been developed to deliver antiproliferative therapeutics. Two drugs, rapamycin and taxol, have been the lead compounds for testing the idea of a drug-eluting stent. These drugs have been successful largely because of the solid mechanistic understanding of their effects and extensive preclinical examination. The result of these years of work is that the rapamycin-coated stent entered the US market in April of 2003, and the taxol-coated stent appears poised to follow soon.
FRI0452 Nailfold capillaroscopy in antisynthetase syndrome (NASCAR): results of a multicenter, international study of the american and european network of antisynthetase syndrome (AENEAS)
Authors: M. Sebastiani, K. Triantafyllias, A. Manfredi, M.A. González-Gay, N. Palmou-Fontana, G. Cassone, U. Drott, C. Delbrück, J. Rojas-Serrano, C. Bertolazzi, L. Nuño, M. Giannini, F. Iannone, E.F. Vicente, S. Castañeda, A. Selva-O’Callaghan, E. Trallero Araguas, G. Emmi, A. Iuliano, J. Bauhammer, N. Miehle, S. Parisi, L. Cavagna, V. Codullo, C.M. Montecucco, F.J. Lopez Longo, J. Martínez-Barrio, J.C. Nieto-González, S. Vichi, M. Confalonieri, R. Bergner, A. Sulli, F. Bonella, F. Furini, C.A. Scirè, C. Specker, S. Barsotti, R. Neri, J. Weinmann-Menke, A. Schwarting, V. Smith, M. Cutolo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Antisynthetase syndrome (ASSD) is an autoimmune disease characterised by the clinical triad arthritis, myositis, and interstitial lung disease (ILD). Despite Raynaud’s phenomenon (RP) is another typical feature of ASSD, nailfold videocapillaroscopy (NVC) assessment of these patients has been only sporadically described, without the elucidating data for clinicians. <h3>Objectives</h3> To describe NVC features of ASSD patients and to investigate possible correlations with clinical and serological features of the disease. <h3>Methods</h3> We retrospectively analysed NVC images of 190 ASSD patients (females/males 3.76, mean age 49.7±12.8 years, mean disease duration 51.2±71.4 months, 133 anti-Jo-1 and 57 non-anti-Jo-1 positive patients). For each patient, we examined number of capillaries, giant capillaries, micro-haemorrhages, avascular areas, ramified capillaries, and the presence of scleroderma (SSc) patterns. Finally, we correlated NVC features with clinical and serological findings of ASSD patients. <h3>Results</h3> NVC abnormalities were observed in 62.1% of AASD patients compared with 29.3% of a group of 75 patients with primary Raynaud’s phenomenon (p&lt;0.001). A SSc-like pattern was detected in 67 (35.3%) patients and it was associated with anti-Jo-1 antibodies (p=0.002) and also with a longer disease duration (p=0.004). Interestingly, there was no significant correlation between the presence of SSc-like pattern and RP, and only 47% of patients with SSc-like pattern had RP. <h3>Conclusions</h3> NVC abnormalities are commonly observed in ASSD, independently to the occurrence of RP. The presence of a SSc-like pattern should let to identify a more defined ASSD subtype and prospective studies could confirm the association with clinical and serological features of ASSD. <h3>Disclosure of Interest</h3> None declared